Arvinas Inc (ARVN)
32.26
-0.56
(-1.71%)
USD |
NASDAQ |
May 06, 16:00
32.27
+0.01
(+0.03%)
Pre-Market: 20:00
Arvinas Enterprise Value: 936.19M for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 936.19M |
| May 03, 2024 | 974.31M |
| May 02, 2024 | 947.76M |
| May 01, 2024 | 951.17M |
| April 30, 2024 | 902.83M |
| April 29, 2024 | 911.68M |
| April 26, 2024 | 943.68M |
| April 25, 2024 | 891.25M |
| April 24, 2024 | 955.25M |
| April 23, 2024 | 1.055B |
| April 22, 2024 | 1.116B |
| April 19, 2024 | 1.104B |
| April 18, 2024 | 1.074B |
| April 17, 2024 | 1.017B |
| April 16, 2024 | 1.017B |
| April 15, 2024 | 1.104B |
| April 12, 2024 | 1.211B |
| April 11, 2024 | 1.277B |
| April 10, 2024 | 1.241B |
| April 09, 2024 | 1.332B |
| April 08, 2024 | 1.303B |
| April 05, 2024 | 1.289B |
| April 04, 2024 | 1.320B |
| April 03, 2024 | 1.367B |
| April 02, 2024 | 1.398B |
| Date | Value |
|---|---|
| April 01, 2024 | 1.490B |
| March 28, 2024 | 1.550B |
| March 27, 2024 | 1.554B |
| March 26, 2024 | 1.531B |
| March 25, 2024 | 1.509B |
| March 22, 2024 | 1.593B |
| March 21, 2024 | 1.691B |
| March 20, 2024 | 1.746B |
| March 19, 2024 | 1.637B |
| March 18, 2024 | 1.640B |
| March 15, 2024 | 1.793B |
| March 14, 2024 | 1.785B |
| March 13, 2024 | 1.904B |
| March 12, 2024 | 1.836B |
| March 11, 2024 | 1.838B |
| March 08, 2024 | 1.942B |
| March 07, 2024 | 1.985B |
| March 06, 2024 | 1.871B |
| March 05, 2024 | 1.920B |
| March 04, 2024 | 1.904B |
| March 01, 2024 | 1.960B |
| February 29, 2024 | 1.870B |
| February 28, 2024 | 1.868B |
| February 27, 2024 | 2.009B |
| February 26, 2024 | 2.062B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-217.05M
Minimum
Oct 27 2023
4.699B
Maximum
Jul 29 2021
1.418B
Average
1.123B
Median
Jul 21 2020
Enterprise Value Benchmarks
| Pfizer Inc | 217.89B |
| Bristol-Myers Squibb Co | 135.05B |
| Janux Therapeutics Inc | 2.869B |
| Geron Corp | 1.852B |
| Verastem Inc | 202.60M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -154.80M |
| Revenue (Quarterly) | -43.10M |
| Total Expenses (Quarterly) | 122.20M |
| EPS Diluted (Quarterly) | -2.53 |
| Earnings Yield | -20.15% |
| Normalized Earnings Yield | -20.15 |